The clinicopathological roles of Aurora kinase protein have not been studied in depth in colorectal cancer. The aim of the present study is to investigate the clinicopathological roles of Aurora kinase protein expression in a large cohort of patients with colorectal adenocarcinoma with tight methodology and close follow-up. Aurora kinase protein expression was investigated in 200 patients (110 men, 90 women) with colorectal adenocarcinomas by immunohistochemistry. The findings were correlated with the clinicopathological features, p16 expression and telomerase activity of colorectal adenocarcinomas. Aurora kinase protein was detected in 48.5%
INTRODUCTION
Colorectal cancer is amongst the most common malignancy found in the Western world and usually ranks high in incidence and mortality among malignancies in those countries [1] . There is evidence that research in the molecular pathway of cancers contributes directly to improve the care of patients with colorectal cancer by more accurately refining prognosis and selecting the most appropriate adjuvant therapy for individual patients with colorectal cancer [2] . For instances, studies of inhibitors targeting the molecular pathway of cancer provide evidences of potential adjuvant treatment for cancers with aggressive behavior [3] . One of the newest classes of drugs on clinical trial is known as Aurora kinase inhibitors [4] .
The Aurora kinas family is a collection of highly related serine/threonine kinases that are key regulators of mitosis. Aurora has evolved into three related kinases known as Aurora-A, Aurora-B, and Aurora-C [5] . Transfection studies have established Aurora A as a bone fide oncogene. The Aurora-A protein (also designated as STK15, BTAK, AURKA, aurora-2, AIK1 or ARK1) is a centrosome-associated protein and has been implicated in regulatory centrosome function, spindle assembly, spindle maintenance, chromosome segregation, and cytokineses [6] .
The gene for Aurora-A is located on chromosome 20q13.2, a region commonly amplified in malignancies [6] . In fact, amplification of Aurora-A mRNA have been found in many human tumors [7] [8] . Nevertheless, discrepancies between amplification and expression of the protein were reported [6] . Aurora-A is likely to be regulated not only by amplification, but also by other mechanisms such as transcriptional activation and suppression of protein degradation. Thus, studies of protein expression are needed to clarify the roles of the protein in human cancers.
However, the antibody to the protein has become available commercially only very recently. The roles of the Aurora kinase protein expression can therefore be studied in situ in larger number of human cancers.
In colorectal cancer, Aurora kinase mRNA have been found to be amplified.
Bischoff and colleagues showed, by Northern blot, that Aurora kinase RNA expression was increased in 54% (22 of 41) of colorectal cancers [9] . Also, Gerlach and colleagues, using real-time polymerase chain reaction, noted significant difference in Aurora kinase RNA between colorectal cancer and normal tissue [10] . In addition, Takahashi and colleagues have demonstrated that 67.9% (53 of 78) of colorectal cancers were positive for polyclonal antibody HsAIRK1 [11] . Other than these, there is no study on the clinicopathological roles of aurora kinase protein expression. The latter is important as only at risk colorectal cancer patients need adjuvant chemotherapy. Therefore, we investigated Aurora kinase expression in a large consecutive cohort of patients with colorectal cancer in order to determine more definitely its relationship with the different clinicopathological parameters and molecular markers. The current series is the first study to critically determine the clinicopathological roles of expression of Aurora kinase protein in colorectal cancer.
It is also the first that looked at the relationship of Aurora kinase expression with p16 protein expression and telomerase activity in colorectal cancer.
MATERIALS AND METHODS

Clinical data collection
Two hundred consecutive patients (110 men, 90 women) with primary colorectal adenocarcinoma were recruited from the Townsville Hospital in North Queensland, Australia. The age, gender, clinical presentation, management and survival data of these patients were prospectively collected in a computerized database. The median age of the patients was 65 (range, 24 to 92) years. The mean diameter of the tumours was 4.5 cm (range, 0.7 to 16.0cm). Thirty five per cent (n=70) of the carcinomas were located in the proximal colorectum (caecum, ascending colon and transverse colon) and 65% (n=130) were noted in the distal colorectum (descending colon, sigmoid colon and rectum).
Tissue collection and pathology examination
The tissue samples were collected prospectively. Standard blocks were then taken, fixed in 10% formalin and embedded in paraffin wax. Histological sections were cut and stained for haematoxylin and eosin for light microscopic examination.
The histological subtypes were classified using the World Health Organization (WHO) criteria [12] . Mucinous carcinoma was defined as an adenocarcinoma with more than 50% of the tumour composing of extracellular mucin. The carcinomas were staged according to TNM (Tumour, Lymph node and Metastases) classification adopted in American Joint Committee on Cancer [13] .
In this series, 38 mucinous adenocarcinomas in the colorectum were noted.
Features consistent with hereditary non-polyposis colorectal cancer (HNPCC) were noted in 16% (6 of the 38) mucinous adenocarcinomas. The other colorectal cancers were 162 conventional adenocarcinomas. Overall, the adenocarcinomas were welldifferentiated in 7% (n=14), moderately-differentiated in 75% (n=150) and poorlydifferentiated in 18% (n=36). Lymph node metastases were noted in 42% (n=83) and distant metastases were found in 12% (n=24) of the patients. The carcinomas as classified according to TNM were: stage I in 24.5% (n=49), II in 32% (n=64), III in 31.5% (n=63) and IV in 12% (n=24).
Patients' follow-up information
The actuarial survival rate of the patients was calculated from the date of surgical resection of the colorectal carcinomas to the date of death or last follow-up.
Management was by a preagreed standardized multidisciplinary protocol supervised by a senior specialist colorectal surgeon. None of the rectal cancer patients had undergone neoadjuvant radiotherapy or chemotherapy prior to surgery. Pathological diagnosis was also standardized and reviewed by committee criteria, chaired by a senior academic pathologist with a special interest in the field. Follow-up was routinely at 3 monthly intervals for the first 2 years, 6 monthly for the subsequent 3 years, and yearly thereafter. Serum carcinoembryonic antigen (CEA) levels were taken before each visit and imaging investigations 2 years after surgery or earlier as clinically appropriate. Colonoscopy was performed at 1 year after surgery, and repeated as appropriate to the findings and other clinical features at follow-up. 
P16 protein expression
P16 expression was done in 189 patients with colorectal cancer. The experiment was done using the method as described in our previous study [14] . In brief, p16 protein expression was tested using immunohistchemical method. The antibody p16 INK4a used was a mouse monoclonal antibody supplied by Biocare Medical (Cat # CM020, Walnut Creek, CA, USA). Brown nuclear stain was regarded as positive.
Telomerase activity
Fresh tissues were obtained in 23 patients with colorectal carcinoma at the time of surgery to study the telomerase activity. These fresh samples were preserved in RNAlater (Ambion, Austin, TX, USA) within 10 minutes of surgery to prevent degradation of the RNA. They were stored at -80 0 C for the experiment. The telomerase activities of these samples were studied by reflected by hTERT levels using standard method as described in our previous study [15] . In brief, the RNAs from the tissues were extracted and cDNAs were prepared. Quantitative analysis of hTERT was done using real-time polymerse chain reaction using Rotor gene system (Corbett Research, Sydney, Australia). Absolute quantification assay was chosen to analyse both hTERT (target) and glyceraldehydes 3-phosphate dehydrogenase (GAPDH, endogenous control) genes expression. Expression level of hTERT for each sample was normalized by dividing the copy number of hTERT by the corresponding copy number of GAPDH. (Normalized hTERT = copy number of hTERT sample / copy number of GAPDH sample x100)
Statistical analysis
Fisher's exact test or likelihood ratio was used for categorical variables. Telomerase activity was present in all the 23 cases tested. In the patients with positive Aurora kinase protein expression, the hTERT level was 0.66 whereas in those with negative Aurora kinase protein expression, the hTERT level was 1.53 (p=0.005).
Student t-test with
Follow-up data were available for all the patients. Thirty percent (n=61) of the patients died of causes related to the colorectal cancer in the study period. The overall median survival rate for patients with the cancer was 60 months. By KaplanMeier log-rank survival and Cox-multivariate analysis, survival of the patients with colorectal cancer was only associated with the TNM stages of the tumours (p=0.0001). Survival of the patients was not significantly related to patients' age, gender and tumours' differentiation, location, Aurora kinase protein expression (p>0.05). In stage III cancers, patients with Aurora kinase protein had slightly poorer survival rates than other patients (Figure 2 ). The median survival was 60 months with negative Aurora kinase protein expression whereas the median survival was 44 months in patients with Aurora kinase protein expression. However, Kaplan-Meier analysis did not show that expression was significantly predicative of survival (p = 0.08).
Discussion
In this report, we described the first systematic survey of Aurora kinase Apart from the 2 molecular pathways, right sided tumours show significantly less nuclear β-catenin and p53 overexpression than left-sided tumours [16] [17] [18] . Our group noted that p16 protein expression was more often noted in mucinous adenocarcinoma of the distal colorectum [14] . We also demonstrated that telomerase activity was higher in the distal colorectum [15] . In this study, we demonstrated for the first time that Aurora kinase protein was also more frequently noted in the distal colorectum. Thus, the differences in gene expression in different location in colorectum exist and this may have important implications with specifically targeted therapeutic regimens in the future.
In our previous study, we noted that colorectal mucinous adenocarcinoma had distinctive clinicopathological features [14] . In this study, we noted that Aurora kinase protein was less found in colorectal mucinous adenocarcinoma than in conventional colorectal adenocarcinoma. This expression profile supports the notion that the entity is different from conventional adenocarcinoma. Royce and colleagues noted that Aurora-A expression in primary breast carcinomas was correlated with nuclear grade [20] . In our study, we noted that Aurora kinase protein was more often noted in well or moderately-differentiated (grades 1 and 2) colorectal adenocarcinoma when compared to poorly-differentiated (grade 3) colorectal adenocarcinoma.
The current study is the first one documenting the correlations with p16 and Aurora kinase proteins expression in human cancer. The p16 suppressor gene is one of the most commonly studied candidates in the pathogenesis of human neoplasia [21] . p16 gene encodes p16 protein that competes with cyclin D for binding to CDK4. This inhibits the ability of the cyclin D-CDK4 complex to phosphorylate Rb (retinoblastoma) protein, thus causing cell cycle arrest at late G 1 phase. As the carcinogenesis of the Aurora kinase depends on p53-Rb signaling pathway and p16 affects the Rb protein, it is logical that p16 and Aurora kinase proteins co-express in colorectal cancer [6] .
Like Aurora kinase, telomerase is important component in cell division.
Telomere shortens in cell division and needs telomerase to keep the length for further cell division. It is believed that telomerase reactivation in the cell is associated with carcinogenesis and is a critical step in the tumour immortalization process. In our previous study, we demonstrated that telomerase activity was significantly higher in colorectal cancer than non-tumour tissue [15] . In human ovarian and breast lines, Yang and colleagues showed that Aurora kinase induces telomerase activity. In the current study, we also noted that telomerase activity was elevated in all colorectal cancer samples being tested. However, the telomerase activity was higher in tumours with negative Aurora kinase expression. This may indicates that other cellular mechanisms may be more important in the induction of telomerase activity in human colorectal cancer. Nevertheless, the negative association of these proteins needs further investigation.
To conclude, Aurora kinase protein is expressed in a subset of colorectal carcinoma. Also, the expression was found to be related to the distal location, grade of tumour, p16 expression and telomerase activity. These findings may be important to select patients to benefit for clinical trials of aurora kinase inhibitors. 1A. Aurora kinase staining in the nuclei of moderately-differentiated adenocarcinoma.
1B. Aurora kinase staining in the nuclei of poorly-differentiated adenocarcinoma. The survival of patient with stage III colorectal cancer in relationship with Aurora kinase protein expression (p=0.08)
